{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T09:11:53Z","timestamp":1767085913830,"version":"3.48.0"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,12,30]]},"DOI":"10.7759\/cureus.100391","type":"journal-article","created":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T09:09:35Z","timestamp":1767085775000},"source":"Crossref","is-referenced-by-count":0,"title":["Side Effects of First-Line Anti-tubercular Therapy (ATT): Does an Alternative Regimen Exist?"],"prefix":"10.7759","author":[{"given":"Gauri","family":"Goswami","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pradeep","family":"Nirala","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rajeev","family":"Tandon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pulkit","family":"Kalra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohammed","family":"Tariq","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lalit","family":"Singh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","article-title":"Global Tuberculosis Control : Surveillance, Planning, Financing : Who Report 2007","author":"World Health Organization","year":"2009","unstructured":"World Health Organization. Global Tuberculosis Control : Surveillance, Planning, Financing : Who Report 2007. World Health Organization, Geneva; 2009."},{"key":"ref2","unstructured":"Technical operative guidelines for TB control in India 2016. (2016). Accessed. 27\/11\/2025: https:\/\/tbcindia-wp.azurewebsites.net\/technical-and-operational-guidelines-for-tb-control-in-india-2016\/."},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.5005\/jp\/books\/10992_54","article-title":"Chapter-54 Antituberculosis treatment induced hepatotoxicity","author":"Garg PK","year":"2009","unstructured":"Garg PK, Tandon RK. Chapter-54 Antituberculosis treatment induced hepatotoxicity. Tuberculosis. .  Sharma SK, Mohan A (ed): Jaypee Brothers Medical Publishers, New Delhi; 2009. 783-95. 10.5005\/jp\/books\/10992_54"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jceh.2012.07.007","article-title":"A guide to the management of tuberculosis in patients with chronic liver disease","volume":"2","author":"Dhiman RK","year":"2012","unstructured":"Dhiman RK, Saraswat VA, Rajekar H, Reddy C, Chawla YK. A guide to the management of tuberculosis in patients with chronic liver disease. J Clin Exp Hepatol. 2012, 2:260-70. 10.1016\/j.jceh.2012.07.007","journal-title":"J Clin Exp Hepatol"},{"key":"ref5","article-title":"Impact of food and antacids on the pharmacokinetics of anti-tuberculosis drugs: systematic review and meta-analysis","volume":"14","author":"Lin MY","year":"2010","unstructured":"Lin MY, Lin SJ, Chan LC, Lu YC. Impact of food and antacids on the pharmacokinetics of anti-tuberculosis drugs: systematic review and meta-analysis. Int J Tuber Lung Dis. 2010, 14:806-18.","journal-title":"Int J Tuber Lung Dis"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1586\/eri.12.13","article-title":"Cutaneous adverse drug reactions to anti-tuberculosis drugs: state of the art and into the future","volume":"10","author":"Lehloenya RJ","year":"2012","unstructured":"Lehloenya RJ, Dheda K. Cutaneous adverse drug reactions to anti-tuberculosis drugs: state of the art and into the future. Expert Rev Anti Infect Ther. 2012, 10:475-86. 10.1586\/eri.12.13","journal-title":"Expert Rev Anti Infect Ther"},{"key":"ref7","article-title":"Pyrazinamide induced hyperuricemia in patients taking anti-tuberculous therapy","volume":"14","author":"Solangi GA","year":"2004","unstructured":"Solangi GA, Zuberi BF, Shaikh S, Shaikh WM. Pyrazinamide induced hyperuricemia in patients taking anti-tuberculous therapy. J Coll Physicians Surg Pak. 2004, 14:136-8.","journal-title":"J Coll Physicians Surg Pak"},{"key":"ref8","article-title":"Treatment of tuberculosis","volume":"52","author":"American Thoracic Society","year":"2003","unstructured":"American Thoracic Society, CDC, Infectious Diseases Society of America. Treatment of tuberculosis. Morbid Mortal Week Rep. 2003, 52:1-77.","journal-title":"Morbid Mortal Week Rep"},{"key":"ref9","article-title":"Management of tuberculosis in special situations","volume":"22","author":"Bedi RS","year":"2005","unstructured":"Bedi RS. Management of tuberculosis in special situations . Lung India . 2005, 22:138-41.","journal-title":"Lung India"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0012023","article-title":"Tuberculosis management by private practitioners in Mumbai, India: has anything changed in two decades?","volume":"5","author":"Udwadia ZF","year":"2010","unstructured":"Udwadia ZF, Pinto LM, Uplekar MW. Tuberculosis management by private practitioners in Mumbai, India: has anything changed in two decades?. PLoS One. 2010, 5:e12023. 10.1371\/journal.pone.0012023","journal-title":"PLoS One"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0083892","article-title":"Hepatitis C virus co-infection increases the risk of anti-tuberculosis drug-induced hepatotoxicity among patients with pulmonary tuberculosis","volume":"8","author":"Lomtadze N","year":"2013","unstructured":"Lomtadze N, Kupreishvili L, Salakaia A, et al.. Hepatitis C virus co-infection increases the risk of anti-tuberculosis drug-induced hepatotoxicity among patients with pulmonary tuberculosis. PLoS One. 2013, 8:e83892. 10.1371\/journal.pone.0083892","journal-title":"PLoS One"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200206-626OC","article-title":"Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis","volume":"167","author":"Yee D","year":"2003","unstructured":"Yee D, Valiquette C, Pelletier M, Parisien I, Rocher I, Menzies D. Incidence of serious side effects from first-line antituberculosis drugs among patients treated for active tuberculosis. Am J Respir Crit Care Med. 2003, 167:1472-7. 10.1164\/rccm.200206-626OC","journal-title":"Am J Respir Crit Care Med"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0236109","article-title":"The high incidence of severe adverse events due to pyrazinamide in elderly patients with tuberculosis","volume":"15","author":"Kwon BS","year":"2020","unstructured":"Kwon BS, Kim Y, Lee SH, et al.. The high incidence of severe adverse events due to pyrazinamide in elderly patients with tuberculosis. PLoS One. 2020, 15:e0236109. 10.1371\/journal.pone.0236109","journal-title":"PLoS One"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.5005\/jp\/books\/10992_33","article-title":"Tuberculosis in chronic renal failure","author":"Agarwal SK","year":"2009","unstructured":"Agarwal SK. Tuberculosis in chronic renal failure. Tuberculosis. Sharma SK, Mohan A (ed): Jaypee Brothers Medical Publishers, New Delhi; 2009. 338-347. 10.5005\/jp\/books\/10992_33"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.2147\/CIA.S95411","article-title":"The clinical outcomes of oldest old patients with tuberculosis treated by regimens containing rifampicin, isoniazid, and pyrazinamide","volume":"11","author":"Lin HS","year":"2016","unstructured":"Lin HS, Cheng CW, Lin MS, Chou YL, Chang PJ, Lin JC, Ye JJ. The clinical outcomes of oldest old patients with tuberculosis treated by regimens containing rifampicin, isoniazid, and pyrazinamide. Clin Interv Aging. 2016, 11:299-306. 10.2147\/CIA.S95411","journal-title":"Clin Interv Aging"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/376014-side-effects-of-first-line-anti-tubercular-therapy-att-does-an-alternative-regimen-exist","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,30]],"date-time":"2025-12-30T09:09:36Z","timestamp":1767085776000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/376014-side-effects-of-first-line-anti-tubercular-therapy-att-does-an-alternative-regimen-exist"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,30]]},"references-count":15,"URL":"https:\/\/doi.org\/10.7759\/cureus.100391","relation":{},"ISSN":["2168-8184"],"issn-type":[{"type":"print","value":"2168-8184"}],"subject":[],"published":{"date-parts":[[2025,12,30]]}}}